Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM-124E in NASH
NCT02316717Phase 2Completed
- Sponsor
- Immuron Limited
- Start
- Dec 2014
- Primary completion
- Oct 2017
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 3
01
Overview
A Phase 2 trial of IMM-124E in Nonalcoholic steatohepatitis (NASH), sponsored by Immuron Limited. Started Dec 2014; status: completed.
02
Drugs
IMM-124E
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02316717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02316717.